Maxillofacial Surgery

Treatment Options and Timing

At a Glance

Hemifacial Hyperplasia (HFH) treatment involves a staged combination of soft tissue debulking, orthodontics, and jaw surgery, usually delayed until skeletal maturity. Newer targeted therapies, like PI3K inhibitors, are increasingly used to shrink overgrowths and prevent surgical recurrence.

Managing Hemifacial Hyperplasia (HFH) is a marathon, not a sprint. Because the condition involves both soft tissues (like fat and muscle) and hard tissues (bone), treatment is often “staged” over many years to match the patient’s growth ^[1]^[2]. The goal is to balance appearance and function while minimizing the number of procedures needed.

Soft Tissue vs. Hard Tissue Treatment

The approach to treatment depends on which layers of the face are most affected:

Soft Tissue Management: If the overgrowth is primarily fat or muscle, surgeons may perform debulking (removing excess tissue) or recontouring ^[1]^[3]. In some cases, liposuction or fat grafting is used to create a more even look ^[4]^[5].
Hard Tissue (Skeletal) Management: When the jaw bones are uneven, orthognathic surgery (jaw straightening surgery) is used. This may involve moving the upper jaw (maxilla), lower jaw (mandible), or both to align the face and the bite ^[6]^[7].

The Importance of Timing and The Risk of Recurrence

One of the most critical decisions a care team makes is when to operate, balancing the need to function with the risk of the tissue growing back.

Skeletal Timing: Major jaw surgery is almost always delayed until skeletal maturity—the point at which the bones have stopped growing (usually late teens) ^[8]^[9]. If surgery is done too early, the continued growth of the “hyperplastic” side can quickly undo the surgical results ^[8].
Soft Tissue Recurrence (The CIL-F Challenge): While debulking can be done earlier if the airway is blocked, surgery on PIK3CA-driven tissues—particularly Congenital Infiltrating Lipomatosis of the Face (CIL-F)—carries a notoriously high risk of rapid recurrence ^[10]^[11]. Cutting into this tissue can sometimes stimulate it to grow back faster, leading to repetitive surgeries and excessive scar tissue ^[11]. Because of this, surgeons are often highly conservative about operating early for purely cosmetic reasons.

The Role of Orthodontics

Orthodontics is a functional necessity in HFH. A craniofacial orthodontist works closely with the surgeon to “decompensate” (move) teeth into the ideal position for their new jaw alignment before surgery, ensuring stability after the bones are moved ^[2]^[12].

A New Frontier: Targeted Medical Therapy

For decades, surgery was the only option. Today, doctors are using medications that target the “stuck switch” in the PI3K/AKT/mTOR pathway ^[13]^[14].

PI3K Inhibitors (e.g., Alpelisib) & mTOR Inhibitors (e.g., Sirolimus): These drugs specifically block the overactive proteins caused by PIK3CA mutations, shrinking overgrowths and improving symptoms ^[13]^[15].

How do these fit into the timeline? Because surgical recurrence is so common (especially in CIL-F), doctors are increasingly using these targeted therapies as a first-line treatment during childhood to halt progression, or using them right before and after a necessary surgery to prevent the tissue from growing back ^[16]^[17].

Understanding the Risks: It is critical to understand that these drugs are powerful and require intense monitoring. Alpelisib, for example, can cause severe hyperglycemia (high blood sugar) that sometimes requires insulin therapy, as well as significant immunosuppression and skin rashes ^[18]^[19]. Choosing between surgery and targeted therapy is a deeply personal decision that requires a specialized care team.

Common questions in this guide

When is the best time to have jaw surgery for Hemifacial Hyperplasia?

Major jaw surgery is almost always delayed until skeletal maturity, which is usually in the late teens. If surgery is performed too early, the continued growth of the affected side can quickly undo the surgical results.

Will the facial tissue grow back after it is removed?

Yes, there is a high risk of tissue growing back after soft tissue debulking, especially in PIK3CA-driven conditions like CIL-F. Cutting into the tissue can sometimes stimulate it to grow back faster, which is why surgeons are conservative about early cosmetic surgery.

Why do I need orthodontics if I am having jaw surgery?

A craniofacial orthodontist must move your teeth into the ideal position for your new jaw alignment before the operation. This ensures that your bite functions properly and that the surgical results remain stable over time.

How do targeted therapies help treat Hemifacial Hyperplasia?

Targeted therapies like alpelisib or sirolimus are medications that block the overactive proteins causing the tissue growth. They are used to halt progression during childhood or prevent tissue from growing back around the time of surgery.

What are the risks of using PI3K inhibitors like alpelisib?

These powerful medications require intense monitoring. Potential risks include severe high blood sugar (hyperglycemia) that may require insulin, significant immunosuppression, and skin rashes.

Curated prompts to bring to your next appointment.

1.What is the likelihood of this tissue growing back rapidly if we proceed with a debulking surgery now?
2.Do you coordinate with my orthodontist on the specific timing of the jaw surgery?
3.When is the right time to consider starting a PI3K inhibitor like alpelisib?
4.How do we balance the risks of immunosuppression and hyperglycemia from targeted therapy against the risks of multiple surgeries?
5.What are the risks of performing surgery while active growth is still occurring?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (19)

1
Hemifacial hyperplasia: a case series and review of the literature.
Dattani A, Heggie A
International journal of oral and maxillofacial surgery 2021; (50(3)):341-348 doi:10.1016/j.ijom.2020.05.008.
PMID: 32622511
2
Multidisciplinary approach to occlusal rehabilitation in a patient with true hemifacial hyperplasia and temporomandibular joint ankylosis: a case report.
Choi EA, Bae JH, Lee S, et al.
BMC oral health 2024; (24(1)):1525 doi:10.1186/s12903-024-05307-1.
PMID: 39707292
3
Coablator-Assisted Excision of an Obstructing Mass in Congenital Hemifacial Hypertrophy.
Maheshwari J, Vishwakarma R
Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India 2024; (76(3)):2820-2823 doi:10.1007/s12070-024-04525-x.
PMID: 38883473
4
Orthognathic Surgery with Simultaneous Autologous Fat Transfer for Correction of Facial Asymmetry.
Wang YC, Wallace CG, Pai BC, et al.
Plastic and reconstructive surgery 2017; (139(3)):693-700 doi:10.1097/PRS.0000000000003113.
PMID: 28234849
5
Parry-Romberg Syndrome With Hemimasticatory Spasm: A Rare Combination.
Chen GC, Chen MJ, Wei WB, Hao YB
The Journal of craniofacial surgery 2020; (31(2)):e205-e208 doi:10.1097/SCS.0000000000006228.
PMID: 31977713
6
Hemimandibular hyperplasia treated with orthognathic surgery and mandibular body osteotomy.
Kim HL, Choi YJ, Kim H
American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2019; (155(5)):714-724 doi:10.1016/j.ajodo.2017.11.044.
PMID: 31053287
7
Orthognathic Treatment of Skeletal Class III Malocclusion with Severe Facial Asymmetry.
Atik E, Konaş E, Kocadereli İ
Turkish journal of orthodontics 2016; (29(1)):22-26 doi:10.5152/TurkJOrthod.2016.15-00025.
PMID: 30112469
8
Early Mandibular Distraction in Craniofacial Microsomia and Need for Orthognathic Correction at Skeletal Maturity: A Comparative Long-Term Follow-Up Study.
Zhang RS, Lin LO, Hoppe IC, et al.
Plastic and reconstructive surgery 2018; (142(5)):1285-1293 doi:10.1097/PRS.0000000000004842.
PMID: 30511982
9
Modern Mandibular Distraction Applications in Hemifacial Microsomia.
Shakir S, Bartlett SP
Clinics in plastic surgery 2021; (48(3)):375-389 doi:10.1016/j.cps.2021.02.001.
PMID: 34051892
10
Congenital infiltrating lipomatosis of the face with lingual mucosal neuromas associated with a PIK3CA mutation.
Briand C, Galmiche-Rolland L, Vabres P, et al.
Pediatric dermatology 2020; (37(6)):1128-1130 doi:10.1111/pde.14302.
PMID: 32770747
11
Advances in the Treatment of Congenital Infiltrating Lipomatosis of the Face: The Role of PIK3CA Mutations and Microvascular Reconstruction.
Moreno SD, Liu RH, Robbins Q, Burkes J
The Journal of craniofacial surgery 2025; (36(1)):229-233 doi:10.1097/SCS.0000000000010751.
PMID: 39724639
12
Defining the location of the dental midline is critical for oral esthetics in camouflage orthodontic treatment of facial asymmetry.
Kai R, Umeki D, Sekiya T, Nakamura Y
American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2016; (150(6)):1028-1038 doi:10.1016/j.ajodo.2015.10.035.
PMID: 27894524
13
Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
Wenger TL, Ganti S, Bull C, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(11)):2318-2328 doi:10.1016/j.gim.2022.07.026.
PMID: 36066547
14
Alpelisib administration reduced lymphatic malformations in a mouse model and in patients.
Delestre F, Venot Q, Bayard C, et al.
Science translational medicine 2021; (13(614)):eabg0809 doi:10.1126/scitranslmed.abg0809.
PMID: 34613809
15
Evolving medical treatment for vascular malformation.
Pang C, Lee R, Nisbet R, et al.
Phlebology 2026; (41(3)):190-200 doi:10.1177/02683555251361663.
PMID: 40708269
16
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.
Morin G, Degrugillier-Chopinet C, Vincent M, et al.
The Journal of experimental medicine 2022; (219(3)) doi:10.1084/jem.20212148.
PMID: 35080595
17
Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G, Pardo Pastor J, Grande Moreillo C
British journal of clinical pharmacology 2022; (88(8)):3891-3895 doi:10.1111/bcp.15270.
PMID: 35146800
18
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Gallagher EJ, Moore H, Lacouture ME, et al.
NPJ breast cancer 2024; (10(1)):12 doi:10.1038/s41523-024-00613-x.
PMID: 38297009
19
PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption.
Ladraa S, Zerbib L, Bayard C, et al.
Science advances 2022; (8(49)):eade7823 doi:10.1126/sciadv.ade7823.
PMID: 36490341

This page is for informational purposes only and does not replace professional medical advice. Always consult your craniofacial care team to determine the safest treatment timeline for your specific situation.

Get notified when new evidence is published on Hemifacial hyperplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents